Mayne Patent-Cliff Exposure & CMS Drug Spending Portfolio

Mayne (US): 9 reconciled FDA prescription therapies (1.6% 2025 to 2030 cliff risk), $40.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure1.6%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$40.4M
2024 Medicare Part D Spend$16.3M
2024 Medicaid Spend$24.0M
California HCAI SB 17 Filings6 WAC filings (max 123.5% 2-yr change)